MENU
+Compare
BMED
ETF ticker: NYSE ARCA
AS OF
Jan 16 closing price
Price
$25.71
Change
+$0.42 (+1.66%)
Net Assets
3.09M

BMED stock forecast, quote, news & analysis

Category: @Health
BMED
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for BMED with price predictions
Jan 08, 2025

BMED's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for BMED turned positive on January 06, 2025. Looking at past instances where BMED's MACD turned positive, the stock continued to rise in of 35 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BMED's RSI Oscillator exited the oversold zone, of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on January 06, 2025. You may want to consider a long position or call options on BMED as a result. In of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

BMED moved above its 50-day moving average on January 08, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BMED advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .

BMED may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMED declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), Abbott Laboratories (NYSE:ABT), Amgen (NASDAQ:AMGN), Intuitive Surgical (NASDAQ:ISRG), Elevance Health (NYSE:ELV), Boston Scientific Corp (NYSE:BSX), McKesson Corp (NYSE:MCK).

Industry description

The investment seeks to maximize total return. Under normal market conditions, the fund will invest at least 80% of its net assets plus any borrowings for investment purposes in equity securities of companies principally engaged in the health sciences group of industries. While the fund will invest primarily in companies providing products and services for human health, it may also invest in companies whose products or services relate to the growth or survival of animals and plants.

Market Cap

The average market capitalization across the iShares Health Innovation Active ETF ETF is 33.12B. The market cap for tickers in the group ranges from 110.91M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is TNYA at 110.91M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Health Innovation Active ETF ETF was 1%. For the same ETF, the average monthly price growth was 0%, and the average quarterly price growth was 0%. CABA experienced the highest price growth at 32%, while KROS experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the iShares Health Innovation Active ETF ETF was -16%. For the same stocks of the ETF, the average monthly volume growth was -14% and the average quarterly volume growth was 48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 76
Price Growth Rating: 61
SMR Rating: 78
Profit Risk Rating: 74
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
BMED
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
BlackRock ETF Trust100 BELLEVUE PARKWAY
Phone
N/A
Web
www.blackrock.com